X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs DIVIS LABORATORIES - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB DIVIS LABORATORIES DR. REDDYS LAB/
DIVIS LABORATORIES
 
P/E (TTM) x 22.8 32.4 70.3% View Chart
P/BV x 3.1 7.3 42.6% View Chart
Dividend Yield % 0.8 0.6 123.6%  

Financials

 DR. REDDYS LAB   DIVIS LABORATORIES
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
DIVIS LABORATORIES
Mar-18
DR. REDDYS LAB/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs2,8751,142 251.8%   
Low Rs1,888533 354.2%   
Sales per share (Unadj.) Rs930.2146.6 634.6%  
Earnings per share (Unadj.) Rs117.433.0 355.4%  
Cash flow per share (Unadj.) Rs185.838.4 483.7%  
Dividends per share (Unadj.) Rs20.0010.00 200.0%  
Dividend yield (eoy) %0.81.2 70.3%  
Book value per share (Unadj.) Rs844.4222.8 379.0%  
Shares outstanding (eoy) m166.07265.47 62.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.65.7 44.8%   
Avg P/E ratio x20.325.3 80.0%  
P/CF ratio (eoy) x12.821.8 58.8%  
Price / Book Value ratio x2.83.8 75.0%  
Dividend payout %17.030.3 56.3%   
Avg Mkt Cap Rs m395,496222,318 177.9%   
No. of employees `00022.010.8 204.1%   
Total wages/salary Rs m33,5624,561 735.9%   
Avg. sales/employee Rs Th7,032.83,616.0 194.5%   
Avg. wages/employee Rs Th1,527.9423.8 360.6%   
Avg. net profit/employee Rs Th887.7814.9 108.9%   
INCOME DATA
Net Sales Rs m154,48238,915 397.0%  
Other income Rs m3,3751,134 297.5%   
Total revenues Rs m157,85740,049 394.2%   
Gross profit Rs m31,78212,617 251.9%  
Depreciation Rs m11,3481,425 796.4%   
Interest Rs m88913 6,684.2%   
Profit before tax Rs m22,92012,313 186.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,8583,543 108.9%   
Profit after tax Rs m19,5008,770 222.3%  
Gross profit margin %20.632.4 63.5%  
Effective tax rate %16.828.8 58.5%   
Net profit margin %12.622.5 56.0%  
BALANCE SHEET DATA
Current assets Rs m111,10145,351 245.0%   
Current liabilities Rs m58,9736,507 906.3%   
Net working cap to sales %33.799.8 33.8%  
Current ratio x1.97.0 27.0%  
Inventory Days Days79127 62.6%  
Debtors Days Days9495 99.0%  
Net fixed assets Rs m101,24521,160 478.5%   
Share capital Rs m830531 156.3%   
"Free" reserves Rs m139,40658,625 237.8%   
Net worth Rs m140,23659,156 237.1%   
Long term debt Rs m22,0000-   
Total assets Rs m224,65667,832 331.2%  
Interest coverage x26.8926.8 2.9%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.70.6 119.9%   
Return on assets %9.112.9 70.1%  
Return on equity %13.914.8 93.8%  
Return on capital %14.920.8 71.7%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m88,67332,359 274.0%   
Fx outflow Rs m19,1049,042 211.3%   
Net fx Rs m69,56923,317 298.4%   
CASH FLOW
From Operations Rs m28,7047,759 370.0%  
From Investments Rs m-7,727-4,783 161.6%  
From Financial Activity Rs m-21,326-3,142 678.8%  
Net Cashflow Rs m-314-166 189.2%  

Share Holding

Indian Promoters % 25.5 52.0 49.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 11.8 45.8%  
FIIs % 35.3 19.0 185.8%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 17.2 89.0%  
Shareholders   75,885 31,796 238.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 305 Points Lower; FMCG and Finance Stocks Witness Huge Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day deep in the red.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jul 22, 2019 03:35 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - WOCKHARDT COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS